Flexion Therapeutics

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, that specializes in the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company's primary product, ZILRETTA, is an intra-articular injection approved for managing knee pain associated with osteoarthritis in the United States. In addition to ZILRETTA, Flexion is advancing several other innovative treatments, including FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate knee pain, and FX301, a NaV1.7 inhibitor designed for post-operative pain management. Founded in 2007, Flexion Therapeutics aims to enhance the effectiveness of local therapies while partnering with other pharmaceutical and biotechnology companies to expand its product offerings and share development risks.